These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

855 related items for PubMed ID: 11916912

  • 1. Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose.
    Greenbaum CJ, Prigeon RL, D'Alessio DA.
    Diabetes; 2002 Apr; 51(4):951-7. PubMed ID: 11916912
    [Abstract] [Full Text] [Related]

  • 2. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.
    Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC.
    Diabetes; 1996 Nov; 45(11):1524-30. PubMed ID: 8866556
    [Abstract] [Full Text] [Related]

  • 3. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.
    Quddusi S, Vahl TP, Hanson K, Prigeon RL, D'Alessio DA.
    Diabetes Care; 2003 Mar; 26(3):791-8. PubMed ID: 12610039
    [Abstract] [Full Text] [Related]

  • 4. Characterisation of beta-cell dysfunction of impaired glucose tolerance: evidence for impairment of incretin-induced insulin secretion.
    Fritsche A, Stefan N, Hardt E, Häring H, Stumvoll M.
    Diabetologia; 2000 Jul; 43(7):852-8. PubMed ID: 10952457
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
    Vilsbøll T, Toft-Nielsen MB, Krarup T, Madsbad S, Dinesen B, Holst JJ.
    Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
    [Abstract] [Full Text] [Related]

  • 6. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
    Vilsbøll T, Krarup T, Sonne J, Madsbad S, Vølund A, Juul AG, Holst JJ.
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
    [Abstract] [Full Text] [Related]

  • 7. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
    Vilsbøll T, Knop FK, Krarup T, Johansen A, Madsbad S, Larsen S, Hansen T, Pedersen O, Holst JJ.
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
    [Abstract] [Full Text] [Related]

  • 8. The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects.
    Elahi D, McAloon-Dyke M, Fukagawa NK, Meneilly GS, Sclater AL, Minaker KL, Habener JF, Andersen DK.
    Regul Pept; 1994 Apr 14; 51(1):63-74. PubMed ID: 8036284
    [Abstract] [Full Text] [Related]

  • 9. A novel hyperglycaemic clamp for characterization of islet function in humans: assessment of three different secretagogues, maximal insulin response and reproducibility.
    Fritsche A, Stefan N, Hardt E, Schützenauer S, Häring H, Stumvoll M.
    Eur J Clin Invest; 2000 May 14; 30(5):411-8. PubMed ID: 10809901
    [Abstract] [Full Text] [Related]

  • 10. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects.
    Kjems LL, Holst JJ, Vølund A, Madsbad S.
    Diabetes; 2003 Feb 14; 52(2):380-6. PubMed ID: 12540611
    [Abstract] [Full Text] [Related]

  • 11. Insulin secretory capacity and the regulation of glucagon secretion in diabetic and non-diabetic alcoholic cirrhotic patients.
    Kruszynska YT, Goulas S, Wollen N, McIntyre N.
    J Hepatol; 1998 Feb 14; 28(2):280-91. PubMed ID: 9514541
    [Abstract] [Full Text] [Related]

  • 12. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.
    Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA.
    Diabetes Care; 1996 Jun 14; 19(6):580-6. PubMed ID: 8725855
    [Abstract] [Full Text] [Related]

  • 13. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
    Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W.
    J Clin Invest; 1993 Jan 14; 91(1):301-7. PubMed ID: 8423228
    [Abstract] [Full Text] [Related]

  • 14. Examining the effects of hyperglycemia on pancreatic endocrine function in humans: evidence for in vivo glucotoxicity.
    Solomon TP, Knudsen SH, Karstoft K, Winding K, Holst JJ, Pedersen BK.
    J Clin Endocrinol Metab; 2012 Dec 14; 97(12):4682-91. PubMed ID: 23043193
    [Abstract] [Full Text] [Related]

  • 15. Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight.
    Schou JH, Pilgaard K, Vilsbøll T, Jensen CB, Deacon CF, Holst JJ, Vølund A, Madsbad S, Vaag AA.
    J Clin Endocrinol Metab; 2005 Aug 14; 90(8):4912-9. PubMed ID: 15899957
    [Abstract] [Full Text] [Related]

  • 16. Diminished insulin secretory response to glucose but normal insulin and glucagon secretory responses to arginine in a family with maternally inherited diabetes and deafness caused by mitochondrial tRNA(LEU(UUR)) gene mutation.
    Brändle M, Lehmann R, Maly FE, Schmid C, Spinas GA.
    Diabetes Care; 2001 Jul 14; 24(7):1253-8. PubMed ID: 11423511
    [Abstract] [Full Text] [Related]

  • 17. Glucagon-like peptide 1 improves the ability of the beta-cell to sense and respond to glucose in subjects with impaired glucose tolerance.
    Byrne MM, Gliem K, Wank U, Arnold R, Katschinski M, Polonsky KS, Göke B.
    Diabetes; 1998 Aug 14; 47(8):1259-65. PubMed ID: 9703326
    [Abstract] [Full Text] [Related]

  • 18. Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance.
    Ritzel R, Schulte M, Pørksen N, Nauck MS, Holst JJ, Juhl C, März W, Schmitz O, Schmiegel WH, Nauck MA.
    Diabetes; 2001 Apr 14; 50(4):776-84. PubMed ID: 11289042
    [Abstract] [Full Text] [Related]

  • 19. Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)--evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins.
    Vaag AA, Holst JJ, Vølund A, Beck-Nielsen HB.
    Eur J Endocrinol; 1996 Oct 14; 135(4):425-32. PubMed ID: 8921824
    [Abstract] [Full Text] [Related]

  • 20. Mixed Meal and Intravenous L-Arginine Tests Both Stimulate Incretin Release Across Glucose Tolerance in Man: Lack of Correlation with β Cell Function.
    Ruetten H, Gebauer M, Raymond RH, Calle RA, Cobelli C, Ghosh A, Robertson RP, Shankar SS, Staten MA, Stefanovski D, Vella A, Wright K, Fryburg DA, Foundation for the NIH Biomarkers Consortium Beta Cell Project Team.
    Metab Syndr Relat Disord; 2018 Oct 14; 16(8):406-415. PubMed ID: 30117761
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.